Form 4: X4 Pharmaceuticals COO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Mary DiBiase, COO of X4 Pharmaceuticals, sold 2,642 shares of common stock on September 9, 2024, to cover personal income tax obligations related to a restricted stock unit award.
Summary
- On September 9, 2024, Mary DiBiase, the Chief Operating Officer of X4 Pharmaceuticals, sold 2,642 shares of the company's common stock.
- The sale was executed at a weighted average price of $0.6577 per share, with individual transactions ranging from $0.6548 to $0.6646.
- The transaction was made to cover personal income tax obligations arising from the settlement of a restricted stock unit award.
- Following the sale, DiBiase directly owns 289,110 shares of X4 Pharmaceuticals.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 2, 2023.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (stock sale for tax obligations) and doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations are a common practice among corporate executives when restricted stock units vest. The use of a 10b5-1 trading plan is a standard method to avoid accusations of insider trading.
Comparison to Industry Standards
- The sale of shares to cover tax obligations is a common practice among corporate executives, especially after the vesting of restricted stock units (RSUs).
- Similar transactions are frequently observed among executives at comparable pharmaceutical companies such as BioCryst Pharmaceuticals and Global Blood Therapeutics.
- The use of a Rule 10b5-1 trading plan is a standard practice to ensure compliance with insider trading regulations, aligning with industry best practices.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, but the explanation provided (tax obligations) mitigates this concern.
- The transaction is unlikely to have a significant impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| June 2, 2023 | Date of adoption of Rule 10b5-1 trading plan. |
| September 9, 2024 | Date of stock sale transaction. |
| September 11, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.